References
Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21:1067–96.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.
Cooperberg MR, Meeks W, Fang R, Gaylis FD, Catalona WJ, Makarov DV. Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US. JAMA Netw Open. 2023;6:e231439.
Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA. 2015;314:80.
Liu Y, Hall IJ, Filson C, Howard DH. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urol Oncol. 2021;39:432.e1–432.e10.
Gravas S, Malde S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, et al. From BPH to male LUTS: a 20-year journey of the EAU guidelines. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00700-3.
Bajpai RR, Razdan S, Sanchez-Gonzalez MA, Reddy BN, Razdan S. Robot-assisted radical prostatectomy after prior transurethral resection of prostate: an analysis of perioperative, functional, pathologic, and oncologic outcomes. J Endourol. 2022;36:1063–9.
Kretschmer A, Mazzone E, Barletta F, Leni R, Heidegger I, Tsaur I, et al. Initial experience with radical prostatectomy following holmium laser enucleation of the prostate. Eur Urol Focus. 2021;7:1247–53.
Liadi Y, Campbell T, Dike P, Harlemon M, Elliott B, Odero-Marah V. Prostate cancer metastasis and health disparities: a systematic review. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00667-1.
Scheipner L, Incesu RB, Morra S, Baudo A, Assad A, Jannello LMI, et al. Characteristics of incidental prostate cancer in the United States. Prostate Cancer Prostatic Dis. 2023. https://doi.org/10.1038/s41391-023-00742-7.
Capitanio U, Autorino R, Bandini M, Briganti A, Cheng L, Cooperberg MR, et al. Incidental prostate cancer (cT1a–cT1b) Is a relevant clinical and research entity and should be fully discussed in the international prostate cancer guidelines. Eur Urol Oncol. 2022;5:256–8.
Han EA, Nandalur KR, Morgan MA, Arora SS, Loening AM, Bivalacqua TJ, et al. MRI of benign prostatic hyperplasia: important pre- and posttherapeutic considerations. RadioGraphics. 2023;43 https://doi.org/10.1148/rg.220096.
Author information
Authors and Affiliations
Contributions
Conceptualization and supervision: EB, RA; Data extraction: EB; Data analysis and interpretation: LCL, RSF; Manuscript drafting: EB, AF, FD; Statistical review: AB; Scientific and grammatical review: CL, CD, RA. All authors approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Bologna, E., Licari, L.C., Ditonno, F. et al. Benign prostatic hyperplasia during active surveillance for prostate cancer: is it time to define management strategies?. Prostate Cancer Prostatic Dis (2024). https://doi.org/10.1038/s41391-024-00837-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41391-024-00837-9
- Springer Nature Limited